A clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio’s main focus is on its HCV NS5A inhibitor program, currently undergoing clinical studies and is well positioned to compete in the growing HCV therapy market.
Investors 1
| Date | Name | Website |
| - | Bay City C... | baycitycap... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 12.02.2008 | “Drug engineer” Numerate rises from the ashes of Pharmix | (UPDATED: See below.) Numerate, a San Bruno, Calif., “drug engineer,” said it has acquired all inte... | venturebea... |
| 29.08.2007 | Life sciences briefing: Wednesday, Aug. 29, 2007 | (UPDATED at 3:10pm PT: See below.) Featured companies: Agendia, EndoGastric Solutions, FlowCo, Gent... | venturebea... |